Lundbeck Restructures Around 5 Key Products; 1,000 Jobs To Go
This article was originally published in Scrip
Executive Summary
Kåre Schultz, the new CEO at H. Lundbeck A/S, has wasted little time in making big decisions. Just three months after taking up the top job at the Danish pharma firm, following a dramatic exit from larger cross-town rival Novo Nordisk, he has announced that Lundbeck's previous restructuring attempts in Europe have not gone far enough. Lundbeck is going to focus on five key products, close early stage R&D programs, and cut 1,000 jobs.